Pharma: Clinic Roundup

• Pfizer Inc., of New York, said the Phase III INTORSECT study testing Torisel (temsirolimus) in patients with advanced renal cell carcinoma whose disease had progressed on or after Sutent (sunitinib malate) therapy did not meet the primary endpoint of prolonging progression-free survival (PFS) when compared to Nexavar (sorafenib, Onyx Pharmaceuticals Inc. and Bayer AG).